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Abstract
Objective: Depressive disorders are common among about 50% of the patients 
with drug-resistant temporal lobe epilepsy (TLE). The underlying etiology remains 
elusive, but hypothalamus-pituitary-adrenal (HPA) axis activation due to changes 
in glucocorticoid receptor (GR) protein expression could play an important role. 
Therefore, we set out to investigate expression of the GR in the hippocampus, an 
important brain region for HPA axis feedback, of patients with drug-resistant TLE, 
with and without comorbid depression.
Methods: GR expression was studied using immunohistochemistry on hippocampal 
sections from well-characterized TLE patients with depression (TLE + D, n = 14) 
and without depression (TLE − D, n = 12) who underwent surgery for drug-resistant 
epilepsy, as well as on hippocampal sections from autopsy control cases (n = 9). 
Video–electroencephalography (EEG), magnetic resonance imaging (MRI), and 
psychiatric and memory assessments were performed prior to surgery.
Results: Abundant GR immunoreactivity was present in dentate gyrus granule 
cells and CA1 pyramidal cells of controls. In contrast, neuronal GR expression was 
lower in patients with TLE, particularly in the TLE + D group. Quantitative analy-
sis showed a smaller GR+ area in TLE + D as compared to TLE − D patients and 
controls. Furthermore, the ratio between the number of GR+/NeuN+ cells was lower 
in patients with TLE + D as compared to TLE − D and correlated negatively with 
the depression severity based on psychiatric history. The expression of the GR was 
also lower in glial cells of TLE + D compared to TLE − D patients and correlated 
negatively to the severity of depression.
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1 |  INTRODUCTION
Depression disorders are among the most common psychi-
atric comorbid conditions in patients with drug-resistant 
temporal lobe epilepsy (TLE). Its prevalence ranges between 
30% and 35%, reaching the highest prevalence (50%) at spe-
cialized epilepsy centers.1,2,3 Furthermore, a history of de-
pression is frequently found in patients with epilepsy,4 and 
a positive correlation between the development of seizures 
and depressive-like symptoms has been demonstrated in 
various animal models of epilepsy, suggesting a bidirectional 
relationship between depression and epilepsy.3,5,6 Comorbid 
depression is further associated with a poor quality of life, in-
creased suicidal risk, higher medical costs, and an increased 
risk of developing drug-resistant epilepsy.3,7
The underlying pathogenic mechanisms remains un-
known, but alterations in hippocampal neuroplasticity due 
to an increased activity of the hypothalamus-pituitary-adre-
nal (HPA) axis is frequently observed in major depression 
and likely constitutes a common pathway that may also be 
disturbed in the combination of TLE and depression. Hence, 
disturbances in HPA axis activity have been implicated as a 
possible pathogenic mechanism underlying the association 
between both pathologies.5,8,9
In clinical practice, epilepsy surgery is performed on pa-
tients with severe, drug-resistant TLE. The most common 
histopathological alteration found in these patients is hip-
pocampal sclerosis.10,11 The hippocampus is further partic-
ularly sensitive to glucocorticoids (GCs), important steroid 
hormones released from the adrenal gland after stress. Both, 
mineralocorticoid receptors (MRs) and glucocorticoid recep-
tors (GRs) are highly expressed in various subregions of the 
hippocampus,12,13 and their activation following GC binding 
exerts negative feedback inhibition of HPA axis activity.14,15 
Hippocampal GRs further regulate neuronal excitability,16-18 
and particularly in the dentate gyrus, they are involved in 
neuroplasticity and neurogenesis.14
It has been reported that high glucocorticoids levels in-
duced by stress can affect epilepsy and may increase sei-
zures.15,16 For example, corticosterone hypersecretion has 
been found after status epilepticus in rodents.17 In addi-
tion, corticosterone administration and experimental stress-
ors enhance neuronal excitability in the hippocampus,16,18 
changes that may be reversed with GR and MR antagonists.19 
Furthermore, patients with TLE who are exposed to a psy-
chosocial stress challenge have higher levels of cortisol,20 
whereas stressful events and particularly early life stressors 
increase the risk for seizures.19 Furthermore, a persistent 
HPA axis hyperactivity has been observed after seizures in 
patients with epilepsy, suggesting an impairment of the in-
hibitory control of the HPA system.9
Several groups have investigated the expression of GRs in 
animal models with depression and/or chronic stress,12,21,22-25 
and a few studies have been done on GRs in postmortem hip-
pocampal tissues from patients with depression.13,25-29 So far, 
only a few addressed hippocampal GR expression in exper-
imental models of epilepsy29 and/or (resected) brain tissue 
from patients with epilepsy.31,32 To the best of our knowl-
edge, the GR has not been studied in the hippocampus of 
patients with epilepsy and depression; we therefore set out 
to study for the first time hippocampal expression of GRs 
in a well-characterized cohort of patients with drug-resistant 
TLE, with and without comorbid depression, as well as in 
control subjects.
Significance: Reduced hippocampal GR expression may be involved in the etiology 
of depression in patients with TLE and could constitute a biological marker of depres-
sion in these patients.
K E Y W O R D S
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Key Points
• Depression is the most common psychiatric co-
morbidity in patients with drug-resistant temporal 
lobe epilepsy (TLE).
• Lower expression of the glucocorticoid receptor 
(GR) was found in neurons and glia within the 
hippocampus of patients with TLE, particularly 
with comorbid depression.
• GR expression correlated negatively with the se-
verity of depression score, which was based on 
psychiatric history.
• Lower GR expression in depressed patients with 
epilepsy is consistent with possible alterations in 
hypothalamus-pituitary-adrenal (HPA) activity in 
these patients.
• GR expression may be involved in the pathogene-
sis of comorbid depression in TLE and could con-
stitute a potential biological marker of depression 
in patients with TLE.
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2 |  METHODS
2.1 | Study design and patient selection
Hippocampal samples obtained from patients who underwent 
surgery for drug-resistant TLE according to the criteria of 
Kwan et al (2010)33 were selected within the period from 
2006 to 2016. All patients underwent surgery at the epilepsy 
center of the Ramos Mejía Hospital and/or El Cruce Hospital, 
Buenos Aires, Argentina. The immunohistochemical proce-
dures were performed at the department of neuropathology of 
the Amsterdam UMC, The Netherlands.
We included samples from patients who had completed 
the routine psychiatric assessment protocol before surgery 
and who had signed the approved informed consent for par-
ticipation. The psychiatric assessment protocol started at the 
epilepsy center in 2001 as part of a clinical research project 
and is now considered a routine measure in all patients before 
epilepsy surgery.34 All patients were receiving their habitual 
medication at the moment of surgery and no one had received 
glucocorticoids anywhere before surgery.
Samples included in this study were grouped according to 
the following criteria for depression. Depression was considered 
positive when patients had experienced at least one current or 
past interictal episode of major depression and/or other depres-
sive disorder, according to the Axis I of the fourth edition of the 
Diagnostic and Statistical Manual of Mental Disorders (DSM) 
IV classification using Structured Clinical Interview for DSM 
Disorders (SCID) I (dysthymia, major depression with or with-
out psychotic symptoms and/or recurrent depression, bipolar 
disorder).35,36 Patients with primary chronic interictal psychiat-
ric disorders according to other sections in Axis I of DSM IV (ie, 
chronic psychosis, current posttraumatic stress disorder, and se-
vere anxiety disorder) were excluded, as were patients with men-
tal retardation (IQ < 70 and/ or attendance at a special school). 
The study was approved by the ethics committee of the Ramos 
Mejía and El Cruce Hospitals, in accordance with the Ethical 
Standards laid down in the 1964 Declaration of Helsinki, and 
full informed consent procedures for participation.
2.2 | Diagnosis of drug-resistant TLE, video-
EEG evaluation, and magnetic resonance imaging
(See Appendix S1.)
2.3 | Neuropsychological assessment
All patients underwent a neuropsychological assessment be-
fore surgery, which was undertaken by trained specialists. 
Verbal memory was determined using the Rey Auditory Verbal 
Learning Test (RAVLT), Spanish Version,37 consisting of 
reading a list of words in five different trials and then recover-
ing the immediate memory, differed memory, and recognition 
in each trial. For visual memory the Rey-Osterrieth Complex 
Figure Test (RCFT) was used. This nonverbal test consists of 
a visual design that is presented to patients who have to copy 
and then reproduce immediately after the visual presenta-
tion (immediate recall) and after 30 minutes (delayed recall). 
Because there are no regional normative data for these tests 
for the Argentinian population, international data were used to 
compare our results.38 To measure the cognitive status, z-scores 
were obtained by comparing each individual result of each test 
with the normal data corrected by age and sex.38 According to 
the high correlation observed between the type of memory and 
the hippocampal sclerosis laterality,39 we considered the z-score 
for visuospatial memory in patients with a right focus, and the 
z-score for verbal memory in patients with a left focus.
2.4 | Psychiatric assessment
All patients included in this study also underwent a com-
plete psychiatric assessment prior to surgery. Psychiatric as-
sessment was performed by trained psychiatrists according 
to a standardized protocol especially designed for patients 
with drug-resistant epilepsy.6,34 Psychiatric history was 
obtained from each patient and relatives, complemented 
by information from families. The psychiatric semiology 
of the witnessed examination was supplemented with the 
Structured Clinical Interview (SCID) Spanish version for 
DSM IV Axis I diagnoses, and with SCID I and SCID II for 
personality disorders.35 Diagnosis of depression was based 
on DSM IV classification and SCID results. In addition, all 
patients were assessed according to the Global Assessment 
of Functioning (GAF) of the DSM IV and to the Beck 
Depression scale. The GAF is a 100-point tool that rates 
overall psychological, social, and occupational functioning 
in relation to psychiatric symptoms and is included in the 
DSM IV in the section on multiaxial assessments (Axis V 
of DSM IV).36 The interviews were carried out in approxi-
mately 2 to 3 hours. To determine depression severity, the 
Beck Depression Inventory II (BDI II), Spanish version, 
was also administered to quantify depression symptoms 
at the moment of psychiatric assessment. The BDI II was 
added to the protocol in 2010.40 Depression severity was 
also determined using an ad hoc composite score based on 
psychiatric history, using factors 1-8 for the diagnosis of 
depression according to the SCID I criteria of DSM-IV. One 
point was added for each positive factor: 1, the presence 
of one episode of an affective disorder codified in Axis I 
of DSM-IV; 2, comorbid psychiatric disorders in Axis I or 
II, present or past (one point for each comorbid disorder); 
3, suicide attempts; 4, psychiatric hospitalization; 5, anti-
depressant treatment (one point was given for patients who 
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had received antidepressants); 6, GAF  ≤60; 7, psychotic 
symptoms associated to depression; and 8, experienced 
more than one episode of an affective disorder (ie, major 
depression and dysthymia or recurrent major depression).
2.5 | Neuropathological diagnosis and 
immunohistochemistry
Resected hippocampi were fixed in 10% buffered formalin 
for >1 week and embedded in paraffin. Coronal hippocampal 
sections at the anterior-medial region of hippocampal body 
were sectioned at 5 µm, mounted on pre-coated glass slides 
(Star Frost, Waldemar Knittel, Braunschweig, Germany) and 
processed. Trained neuropathologists made the neuropatho-
logical diagnosis. Archival material of postmortem control 
hippocampus (postmortem delay was maximum 8 hours) was 
simultaneously processed. Samples were selected matched 
by gender and were otherwise free from known neurological 
injury, drug, and/or alcohol abuse and suicidal events.
Immunohistochemistry was performed to study GR 
protein expression to protocols described before.13,28 
Furthermore, to assess cell type–specific effects, double-la-
beling was performed using markers for astrocytes as well 













































1 18 4 24 6 1 No No DPH, TPM No No 70 n/a 0 1 7 -1.71 11.5 -3.89 R -3.89
2 2 10 25 23 5 MD + P FLX CBZ, VPA, CL No No 55 n/a 6 1 10 -0.40 8 -4.58 R -4.58
3 8 10 22 14 0 MD + P CIT CBZ, LMT Yes Yes 70 n/a 7 1 8 -1.14 9 -4.30 L -1.14
4 7 4 45 38 1 No No CBZ, LMT No No 70 n/a 0 1 4 -1.64 17 -0.54 R -0.54
5 11 4 28 17 3 No No CBZ, LMT No No 80 n/a 0 2 10 -0.46 21 -1.20 R -1.20
6 7 4 21 14 0 No No CBZ, TPM No No 70 n/a 0 1 8 -1.15 22 -0.97 R -0.97
7 12 2 22 10 3 No No DPH, LMT, CL No No 60 11 1 1 11 -0.04 16 -2.48 R -2.48
8 1 3 40 39 0 No No VPA, CL No No 70 6 0 1 9 -0.12 14 -1.14 L -0.12
9 13 9 34 21 3 No No VPA, TPM No No 75 0 0 1 11 -0.07 15 -1.93 R -1.93
10 11 4 29 18 0 No No CBZ, CL No No 70 6 0 1 4 -2.96 18 -2.01 L -2.96
11 3 10 29 26 4 MD + P PARX TPM, VPA, CL Yes Yes 55 25 8 1 4 -2.96 10 3.50 L -2.96
12 25 4 37 12 3 No No CBZ, TPM, CL No No 85 8 0 2 4 -1.76 18.5 -0.69 L -1.76
13 5 6 35 30 2 No No LMT, VPA No No 70 1 0 1 7 -0.94 5 -4.50 R -4.50
14 3 2 41 38 0 No No CBZ, LVT No No 85 6 0 1 4 -1.64 18 -0.34 R -0.34
15 10 6 24 14 0 MD SER LMT, CBZ No No 55 21 5 1 3 -3.00 8 -4.00 L -3.00
16 18 2 34 16 2 No No LVT, VPA No No 60 8 1 1 8 -1.88 7.5 -3.57 R -3.57
17 6 3 17 11 0 MD No OXC, LVT, CL No No 70 29 3 1 8 -1.94 14 -2.37 R -2.37
18 21 2 38 17 3 D No LVT, LCS No No 65 5 2 1 6 -2.00 22 -0.40 L -2.00
19 17 3 53 36 1 MD FLX LMT, LVT, CL No No 55 24 4 1 10 0.00 19 -0.36 L 0.00
20 8 4 31 23 3 MD 1 LVT, LCS No No 65 18 3 1 13 0.64 27 0.69 L 0.64
21 5 3 18 13 0 D No OXC, CL No No 65 n/a 2 NHS 11 -0.32 14 -2.36 L -0.32
22 8 10 25 17 0 MD No TPM, CBZ, DPH No No 55 20 4 1 0 -4.63 13 -3.29 L -4.63
23 20 8 50 30 0 MD SER CBZ No No 55 17 5 1 1 -2.57 11 -2.34 L -2.57
24 2 4 38 36 3 MD + P CIT VPA, PB Yes Yes 50 22 9 1 5 -2.21 22 -0.41 L -2.21
25 7 3 33 26 4 No No LVT, CBZ, CL No No 85 2 0 1 6 -1.86 11.5 -2.70 R -2.70
26 25 3 47 22 0 No No CBZ, LVT, CL No No 75 8 0 NHS 12 0.56 21 0.08 R 0.08
Note: Medical history: 0. No history 1. Perinatal hypoxia. 2. Encephalic trauma 3. Febrile seizures 4. Central Nervous System Infection. 5. Status Epilepticus. GAF:  
Global Assessment of Functioning (DSM IV), Depression: MD, Major Depression; MD + P, Major Depression with psychotic symptoms; D, Dysthymia; n/a, not  
available. Antidepressants: FLX, Fluoxetine; PARX, Paroxetine; CIT, Citalopram; SER, Sertraline. Antiepileptic drugs: CBZ, Carbamazepine; CL, Clonazepam;  
DPH, Diphenylhydantoin; LCS, Lacosamide; LMT, Lamotrigine; LVT, Levetiracetam; PB, Phenobarbital; TPM, Topiramate; VPA, Valproate. Severity of Depression  
score according clinical factors: 0, Absence of depression; 9, Maximum score. HS, Hippocampal Sclerosis; NHS, No hippocampal sclerosis. Laterality of epileptic  
focus: R, Right; L, Left. Z score ipsilateral to the epileptic focus; R, Visual memory; L, Verbal memory.
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as for microglia and for NeuN. Finally, quantitative analysis 
was performed. (For details see supplementary methods.)
2.6 | Statistical analysis
Descriptive statistics was performed, and the chi-square test was 
used to analyze qualitative variables. The normal distribution of 
data was determined using the Shapiro-Wilk test. The Student's 
t test, the one-way analysis of variance (ANOVA), and Pearson 
correlations were applied when a normal distribution was 
found and non-parametric tests (Mann Whitney) and Spearman 
correlations were applied when the data were not normally dis-
tributed (Shapiro-Wilk test < 0.05). IBM SPSS Statistics 22 was 
used to perform statistical analysis. A P-value < 0.05 was as-
sumed to indicate a significant difference.
3 |  RESULTS
3.1 | Clinical data
Hippocampal samples from 12 patients with TLE and depres-
sion (TLE + D; age = 31±12 years; 4 men and 8 women), 14 
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patients with TLE without depression (TLE − D; age = 34± 
8  years; 8 men and 6 women), and 9 postmortem controls 
(age  =  52.9  ±  20.6; 6 men and 3 women, cause of death: 
heart failure = 5, aortic dissection n = 2, pulmonary embo-
lism n = 1, pneumonia n = 1), were included. Postmortem 
samples were selected matched by gender and free from neu-
rological injury, drug and/or alcohol dependency, and sui-
cidal evidences.
The epilepsy duration, the age at epilepsy onset (both 
P  >  .05, Student's t test), and seizure frequency (P  >  .05, 
Mann-Whitney) did not differ between TLE − D and 
TLE + D. Clinical and neuropathological data of TLE − D 
and TLE + D cases are summarized in Table 1.
3.2 | GR expression in neurons
Abundant GR immunoreactivity was present in nuclei of gran-
ule cells within the dentate gyrus of controls (Figures 1A and 
2A) and pyramidal cells of CA1 (Figures 1A and 3A). A pre-
dominant nuclear staining was also found within the granule 
cell layer of TLE − D (Figures 1B and 2B) and TLE + D sam-
ples (Figures 1C and 2C). However, GR immunoreactivity was 
lower in granule cells in TLE − D as compared to controls, and 
the lowest expression was found in TLE + D (Figures 1C and 
2C). GR immunoreactivity was also lower in CA1 pyramidal 
cells in TLE − D (Figures 1B and 3B) as compared to controls 
(Figures  1A and 3A), and the lowest expression was again 
found in TLE + D samples (Figures 1C and 3C).
Quantitative analysis of GR expression in the dentate gyrus 
showed that the total GR+  area (Figure  4) was different be-
tween the three groups (controls, TLE − D, and TLE + D). A 
smaller GR+ area was found in the dentate gyrus of patients 
with TLE  +  D (x  =  535.12, SD  =  206.9) as compared to 
TLE − D (x = 787.01, SD = 264; F = 50.3 (2-33); P = .048; 
One-Way ANOVA-Bonferroni) and as compared to controls 
(x = 1616.57, SD = 284.26; F = 50.3 (2-33); P = .0001; one-
way ANOVA-Bonferroni). Furthermore, the ratio between 
the number of GR+/NeuN + cells was lower in patients with 
TLE + D (x = 0.7, SD = 0.27, rank = 17.1) as compared to TLE 
− D (x = 1.03, SD = 0.24, rank = 9.29; U = 33.50, P = .008; 
Mann-Whitney).
3.3 | GR expression in glial cells
Consistent with earlier reports,13 GR immunoreactivity 
was also found in the nuclei of glia cells (white arrows in 
Figures  2 and 3). Double labeling confirmed that the GR 
was expressed predominantly in the nucleus and co-localized 
with the microglia marker CR3/43 and the astrocyte marker 
GFAP (Figure 5). GR expression was observed in 37.9% of 
the CR3/43+ cells in TLE − D cases vs 40.0% in TLE + D 
cases. GR expression was found in 50.9% of the GFAP+ cells 
in TLE − D vs 48.0% in TLE + D cases.
Quantitative analysis of the GR in glial cells showed 
that the mean optical density among individual GR+  glia 
nuclei was lower in TLE + D patients as compared to TLE 
− D in the granule cell layer/molecular layer (TLE  +  D 
x  =  83.10, SD  =  12.61; TLE-D x  =  95.69, SD  =  15.23; 
F I G U R E  1  GR expression in the hippocampus. GR expression in 
postmortem control hippocampus (A), in the resected hippocampus of 
patients with temporal lobe epilepsy without depression (TLE −D) (B), 
and in patients with temporal lobe epilepsy with depression (TLE + D) 
(C). The black rectangles in the dentate gyrus (DG) and CA1 indicate 
the areas that are shown at high magnification in Figures 2 and 3. Scale 
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t = 2.27; P = .032; Student t test) and in the hilus (TLE + D, 
x  =  80.40, SD  =  11.63; TLE-D x  =  97.34, SD  =  16.54; 
t = 2.96; P = .007; Student t test).
3.4 | Glucocorticoid receptor expression in 
relation to clinical parameters
Regarding the psychiatric parameters related to depression, 
the ratio of GR+/NeuN+  cells correlated negatively with 
depression severity, based on psychiatric history (ad hoc 
composite score; r = −0.528; P =  .006; Spearman correla-
tion), but not with the Beck Inventory (r = −0.359; P = .131; 
Spearman correlation). A tendency toward a positive correla-
tion was found between the ratio of GR+/NeuN+ cells and 
the GAF scores (r = 0.297; P = .141; Spearman correlation). 
In addition, the expression of the GR in glia within the hilus 
correlated negatively with depression severity (ad hoc com-
posite score; r = −0.42; P = .032; Spearman correlation).
With regard to the cognitive variables, memory scores 
(z-score ipsilateral for the epileptic focus) did not differ 
between TLE − D and TLE + D cases (P >  .05, Student t 
test) and did not correlate with GR expression in neurons or 
glial cells (P > .05; Pearson correlation).
With respect to the clinical aspects of epilepsy, the epi-
lepsy duration, age at epilepsy onset, and seizure frequency 
did not correlate with the GR expression in neurons or glial 
cells (Pearson correlation, P > .05).
The distribution of male and female patients in TLE − 
D and TLE + D groups was similar (P > .05, chi-square 
test). Regarding sex and GR expression parameters, the 
expression of the GR in glia was lower in women with 
TLE- D (x = 82.67, SD = 6.23) as compared to men with 
TLE- D (x  =  105.46, SD  =  12.21; t  =  4.15, P  =  .001; 
Student t test). These differences were not observed in 
patients with TLE + D (women x = 86.29, SD = 14.60; 
men x = 76.71, SD = 1.95; t = −1.27; P = .23; Student t 
test). The other GR expression parameters did not differ 
between males and females. GR expression did not cor-
relate with age.
F I G U R E  2  GR expression in the dentate gyrus. GR expression 
was found in neuronal nuclei (black arrows) and cells with glial 
morphology (white arrows) in the dentate gyrus of postmortem 
control hippocampus (A). Lower expression of the GR was evident in 
neurons (black arrows) and glial cells (white arrows) within the dentate 
gyrus of patients with TLE − D (B), and this was most evident in 
patients with TLE + D (C). Scale bar = 50 µm. ml = molecular layer, 
gcl = granule cell layer, TLE − D = temporal lobe epilepsy without 




F I G U R E  3  GR expression in CA1. Abundant GR expression 
was found in neuronal nuclei (black arrows) and cells with glial 
morphology (white arrows) in the pyramidal cell layer of CA1 of 
controls (A). A major loss of pyramidal neurons was observed in the 
CA1 of TLE patients (B and C), and the remaining pyramidal cells 
showed lower GR expression (black arrows). Lower GR expression 
was also observed in glial cells (white arrows) of TLE patients. 
Reduced GR expression was most evident in patients with TLE + D 
(C). Scale bar = 50 µm. TLE − D, temporal lobe epilepsy without 
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4 |  DISCUSSION
Comorbid depression in TLE occurs frequently among 
drug-resistant epilepsy patients and strongly affects their 
quality of life.7,17 As such, it forms an important con-
cern for both psychiatrists and neurologists. Here, hip-
pocampal samples from a cohort of well-characterized 
TLE patients were studied, focusing on the GR because it 
has been proposed to be involved in the pathogenesis of 
depression.5,8,9,15,16
We found lower expression of GRs in the hippocampus 
of TLE patients as compared to controls. Furthermore, TLE 
patients with comorbid depression had lower GR immuno-
reactivity in the hippocampus as compared to TLE patients 
without depression. Watzka et al investigated expression of 
the GR in the brain of patients with TLE and showed that 
MR and GR messenger RNA (mRNA) expression was lower 
in hippocampal tissue than in frontal and temporal lobe cor-
tical tissue of women with epilepsy,32 but in this study they 
did not make a comparison to control brain tissue or between 
patients with and without depression. In another study, higher 
GR gene expression was found in the cortex of drug-resis-
tant TLE patients as compared to controls.31 However, in 
that study the hippocampus was not studied, and the authors 
did not compare TLE patients with and without depression. 
Furthermore, they discussed that no clear picture has emerged 
from GR studies using animal models of epilepsy, since in 
three studies a decrease in GR was observed in the cortex or 
hippocampus after induced seizures, whereas the expression 
increased in the hippocampus in another study.31
In our previous study (using a different cohort), we have 
shown lower calbindin expression (in the basal part of the gran-
ule cell layer), but higher expression in granule cells that were 
dispersed in the molecular layer of dentate gyrus, in patients 
with TLE + D vs TLE − D.6 We discussed that this pattern of 
calbindin expression may contribute to both hyperexcitability 
and neuropsychiatric illness, favoring behavioral and cogni-
tive alterations. Liu et al investigated a large group of epilepsy 
patients (n = 276) and showed indeed that seizure frequency 
was positively associated with depression severity.41 We did 
not observe such differences between epilepsy patients with 
and without depression in the present study, which may be 
explained by our smaller sample size compared to Liu et al; 
F I G U R E  4  Quantitative analysis of GR expression in the dentate 
gyrus showed that GR+ area was different between the three groups 
(controls n = 9, TLE − D n = 14 and TLE + D n = 12; three replicates 
per case). A smaller GR+ area was found in the dentate gyrus of 
patients with TLE + D as compared to TLE – D, and as compared 
to controls. TLE − D, temporal lobe epilepsy without depression; 
TLE + D, temporal lobe epilepsy with depression. *One-way 
ANOVA/Bonferroni P < .05.
F I G U R E  5  GR expression in glial 
cells. GR (purple) colocalized with the 
microglia marker CR3/43(blue) in the 
dentate gyrus of patients with TLE − D 
(A) as well as in TLE + D (C) and the GR 
(purple) also colocalized with the astrocyte 
marker GFAP (blue) in TLE-D (B) as well 
as in TLE + D (D). Insets show higher 
magnification of glial cells. TLE − D, 
temporal lobe epilepsy without depression; 
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however, there was a tendency for a higher seizure frequency 
in our group of patients with epilepsy and depression.
Our findings about reduced GR expression in the hippo-
campus, particularly in TLE patients with depression, are 
comparable to those of other studies on chronic stress and 
depression models. A downregulation of GR mRNA expres-
sion was reported in the rodent hippocampus after chronic 
stress21,22,25 and after chronic corticosterone exposure.23 
Mizoguchi et al further found reduced GR expression in the 
prefrontal cortex after chronic stress24 and also in primates 
lower expression of GR mRNA was reported in the prefrontal 
cortex42 following stress exposure. Similarly, López et al re-
ported a decrease in hippocampal MR and GR expression in 
suicide victims with a history of depression. In addition, sim-
ilar findings were shown by Klok et al27 for the GR and MR 
in major depression in various brain regions including the 
hippocampus, whereas the GR beta isoform that was thought 
to be implicated in GR resistance was found to be very rare 
in the human brain.29 Furthermore, decreased GR mRNA ex-
pression in patients with depression was found exclusively in 
the dentate gyrus.26 A reduction in the MR/GR ratio has been 
reported in the anterior hippocampus from patients with major 
depression.12 Overall, these results suggest that alterations in 
hippocampal GR (and MR) expression are associated with de-
pression. These results appear region- and condition-specific, 
as GR protein level as well as the percentage of GR-containing 
astrocytes were found before to be significantly higher in the 
amygdala in major depression than in bipolar depressed pa-
tients or in control subjects, but these authors focused on older 
depressed patients.28 Furthermore, we showed that the ratio 
of GR+/NeuN+ cells as well as the expression of the GR in 
glia within the hilus correlated negatively with the severity of 
depression as based on psychiatric history (ad hoc compos-
ite score), but not with the Beck Inventory, which provides a 
measure of the severity of depression at the moment of assess-
ment. This indicates the importance of taking into account the 
psychiatric history and highlights that the most recent status 
may not always reflect the observed GR changes in the brain.
Regarding models of epilepsy, abundant evidence has 
demonstrated that HPA activity is enhanced during epilep-
tic seizures,9 but only a few studies identified hippocampal 
GR expression in epileptogenic brain tissues. In experimental 
models with rodents, epileptic discharges and ischemic in-
sults were shown to reduce GR expression in the hippocam-
pal neurons of CA1 and the dentate gyrus neurons.30,43
Sex differences in hippocampal GR expression have 
also been described. Lower GR expression was found in 
the epileptogenic cortex of men compared to women; how-
ever, women showed lower GR expression in the hippo-
campus.32 GR expression is generally not altered during 
aging, although an age-associated GR decline was reported 
in the dentate gyrus of females.13,44 In the current study, 
we observed a lower glial GR content in women with TLE 
- D as compared to men, but these differences were not ob-
served in TLE + D patients. No other differences in GR ex-
pression were observed between female and male patients. 
Most likely, the sample size of this study was too small to 
find further differences.
The GR constitutes a key factor in understanding the 
mechanisms involved in the pathogenesis of TLE and de-
pression, with potential therapeutic implications. Activation 
of the GR has genomic and, also, rapid nongenomic ac-
tions, each of which may affect hippocampal excitability.16 
The MR has a 10-fold higher affinity than the GR for cor-
tisol, so although MR is almost always occupied, the GR 
becomes activated only when circulating levels of cortisol 
increase (ie, under stressful conditions)12,16 and under con-
ditions of epileptic seizures.9,16 The hippocampus and par-
ticularly the dentate gyrus cells further exert an inhibitory 
role on the activity of the HPA axis. This negative feedback 
is involved in termination of the stress response.45 GR dys-
function may contribute to impair the negative feedback of 
the HPA axis, which, in turn, could lead to a feed-forward 
activation of the HPA axis.9 Furthermore, dysregulation of 
the HPA axis and glucocorticoids may affect local and sys-
temic inflammatory mechanisms, which have been found 
to be altered in both TLE and depression models.46 An 
increase in expression of inflammatory markers has been 
described extensively in various epilepsy models47,48, in 
epilepsy models with depression,46 and in depression mod-
els.49 In our current study, patients with TLE had hippo-
campal sclerosis, which is characterized by neuronal loss 
and gliosis. In addition, we found lower expression of the 
GR in glial cells from patients with TLE + D. Thus the re-
duced GR expression in both neurons and glia may indicate 
that TLE + D patients have been more exposed to gluco-
corticoids during life, which may lead to downregulation of 
GRs. As a result of the prolonged downregulation of hippo-
campal GR, the inhibitory influence on the HPA axis could 
have become chronically reduced, thereby stimulating HPA 
activity even further and creating a vicious cycle.
5 |  CONCLUSION
Reduced hippocampal GR expression may be involved 
in the etiology of depression in patients with TLE and 
could constitute a biological marker of depression in these 
patients.
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